Elevated CSF and plasma complement proteins in genetic frontotemporal dementia: results from the GENFI study.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
van der Ende Emma L, Heller Carolin, Sogorb-Esteve Aitana, Swift Imogen J, McFall David, Peakman Georgia, Bouzigues Arabella, Poos Jackie M, Jiskoot Lize C, Panman Jessica L, Papma Janne M, Meeter Lieke H, Dopper Elise G P, Bocchetta Martina, Todd Emily, Cash David, Graff Caroline, Synofzik Matthis, Moreno Fermin, Finger Elizabeth, Sanchez-Valle Raquel, Vandenberghe Rik, Laforce Robert, Masellis Mario, Tartaglia Maria Carmela, Rowe James B, Butler Chris, Ducharme Simon, Gerhard Alexander, Danek Adrian, Levin Johannes, Pijnenburg Yolande A L, Otto Markus, Borroni Barbara, Tagliavini Fabrizio, de Mendonça Alexandre, Santana Isabel, Galimberti Daniela, Sorbi Sandro, Zetterberg Henrik, Huang Eric, van Swieten John C, Rohrer Jonathan D, Seelaar Harro, Genetic Frontotemporal Dementia Initiative (GENFI)
Аннотация
METHODS: We measured the complement proteins C1q and C3b in CSF by ELISAs in 224 presymptomatic and symptomatic GRN, C9orf72 or MAPT mutation carriers and non-carriers participating in the Genetic Frontotemporal Dementia Initiative (GENFI), a multicentre cohort study. Next, we used multiplex immunoassays to measure a panel of 14 complement proteins in plasma of 431 GENFI participants. We correlated complement protein levels with corresponding clinical and neuroimaging data, neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP).
RESULTS: CSF C1q and C3b, as well as plasma C2 and C3, were elevated in symptomatic mutation carriers compared to presymptomatic carriers and non-carriers. In genetic subgroup analyses, these differences remained statistically significant for C9orf72 mutation carriers. In presymptomatic carriers, several complement proteins correlated negatively with grey matter volume of FTD-related regions and positively with NfL and GFAP. In symptomatic carriers, correlations were additionally observed with disease duration and with Mini Mental State Examination and Clinical Dementia Rating scale® plus NACC Frontotemporal lobar degeneration sum of boxes scores.
CONCLUSIONS: Elevated levels of CSF C1q and C3b, as well as plasma C2 and C3, demonstrate the presence of complement activation in the symptomatic stage of genetic FTD. Intriguingly, correlations with several disease measures in presymptomatic carriers suggest that complement protein levels might increase before symptom onset. Although the overlap between groups precludes their use as diagnostic markers, further research is needed to determine their potential to monitor dysregulation of the complement system in FTD.